Journal of Allergy and Clinical Immunology, 2026
Background
Up to 60% of patients with severe asthma are prescribed oral corticosteroids (OCS) despite their adverse effects, increased risks of long-term complications, and development of comorbid conditions.
Objective
We aimed to assess the clinical and economic burden of chronic OCS receipt in treating asthma.
Methods
This retrospective study included real-world data from the IQVIA PharMetrics Plus claims database between January 2015 and December 2019. Adult patients with asthma were classified into 3 non-mutually exclusive groups according to definition of OCS receipt: continuous (≥10 mg/d taken over 90 days), cumulative (≥500 mg taken over 12 months), or burst (≥2 bursts taken over 12 months). Patient demographics, OCS-related and other comorbidities, treatment patterns, health care resource utilization (HRU), and costs were described before and after patients met the definition of chronic OCS receipt.
Results
The OCS continuous (≥10 mg/d), cumulative (≥500 mg), and burst (≥2 bursts) groups included 1358, 43,215, and 46,774 patients, respectively. Before OCS receipt, continuous recipients were older and had higher comorbidity burden than cumulative and burst recipients. After OCS receipt, continuous recipients had higher OCS exposure, higher OCS comorbidity rates, higher asthma-related HRU, and higher asthma-related health care costs than cumulative and burst recipients. Respiratory medication receipt and asthma exacerbation rates were similar across groups, both at baseline and after identification of chronic OCS receipt.
Conclusion
Our findings highlight increased OCS-related comorbidity, HRU, and economic burden after chronic OCS receipt among US patients with asthma.
Authors
Modena B, Bogart M, Averell C, Germain G, Laliberté F, MacKnight SD, Duh MS